Home › Myelofibrosis › Pennsylvania
Myelofibrosis clinical trials in Pennsylvania
8 studies for Myelofibrosis are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- Allegheny Health Network Cancer Institute - West Penn Hospital Location, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07623161A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- UPMC Hillman Cancer Center ( Site 6004), Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06351631Two Step Haplo With Radiation Conditioning
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2025 · NCT05031897SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- West Penn Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
- Fox Chase Cancer Center - Philadelphia, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 3, 2024 · NCT06218628From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.